Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.

Rheumatology (Oxford, England) - 1 Feb 2005

Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y

Abstract excerpt

OBJECTIVES: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoreactive T cells and polyclonally activated B cells that produce autoantibodies. Five SLE patients who failed to respond to conventional immunosuppressants were treated with anti-CD20 antibody (rituximab) and their clinical manifestations and laboratory data were evaluated, including phenotypic analysis of B cells....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Hemolytic, Autoimmune
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, CD20

Share to B7-1 Antigen

Share to CD40 Antigens

Share to Lymphocyte Depletion

Share to Pilot Projects

Share to Rituximab

Source

Identifiers

PMID: 15494350
DOI: 10.1093/rheumatology/keh443

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.PMID 15494350Read ↗

Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.Semantic proximity Read ↗

Depletion of functionally active CD20+ T cells by rituximab treatment.Semantic proximity Read ↗

Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.Semantic proximity Read ↗

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity.Semantic proximity Read ↗

Rituximab resistance.Semantic proximity Read ↗

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.Semantic proximity Read ↗

In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.Semantic proximity Read ↗

A type II anti-CD20 monoclonal antibody efficiently depletes CNS B cells in a mouse model of multiple sclerosisSemantic proximity Read ↗

Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma.Semantic proximity Read ↗

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.Semantic proximity Read ↗

Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.Semantic proximity Read ↗

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.